Exploring candidate biomarkers for rheumatoid arthritis through cardiovascular and cardiometabolic serum proteome profiling
Copyright © 2024 Cuesta-López, Escudero-Contreras, Hanaee, Pérez-Sánchez, Ruiz-Ponce, Martínez-Moreno, Pérez-Pampin, González, Plasencia-Rodriguez, Martínez-Feito, Balsa, López-Medina, Ladehesa-Pineda, Rojas-Giménez, Ortega-Castro, Calvo-Gutiérrez, López-Pedrera, Collantes-Estévez, Arias-de la Rosa and Barbarroja..
Introduction: RA patients are at higher risk of cardiovascular disease, influenced by therapies. Studying their cardiovascular and cardiometabolic proteome can unveil biomarkers and insights into related biological pathways.
Methods: This study included two cohorts of RA patients: newly diagnosed individuals (n=25) and those with established RA (disease duration >25 years, n=25). Both cohorts were age and sex-matched with a control group (n=25). Additionally, a longitudinal investigation was conducted on a cohort of 25 RA patients treated with methotrexate and another cohort of 25 RA patients treated with tofacitinib for 6 months. Clinical and analytical variables were recorded, and serum profiling of 184 proteins was performed using the Olink technology platform.
Results: RA patients exhibited elevated levels of 75 proteins that might be associated with cardiovascular disease. In addition, 24 proteins were increased in RA patients with established disease. Twenty proteins were commonly altered in both cohorts of RA patients. Among these, elevated levels of CTSL1, SORT1, SAA4, TNFRSF10A, ST6GAL1 and CCL18 discriminated RA patients and HDs with high specificity and sensitivity. Methotrexate treatment significantly reduced the levels of 13 proteins, while tofacitinib therapy modulated the expression of 10 proteins. These reductions were associated with a decrease in DAS28. Baseline levels of SAA4 and high levels of BNP were associated to the non-response to methotrexate. Changes in IL6 levels were specifically linked to the response to methotrexate. Regarding tofacitinib, differences in baseline levels of LOX1 and CNDP1 were noted between non-responder and responder RA patients. In addition, response to tofacitinib correlated with changes in SAA4 and TIMD4 levels.
Conclusion: In summary, this study pinpoints molecular changes linked to cardiovascular disease in RA and proposes candidate protein biomarkers for distinguishing RA patients from healthy individuals. It also highlights how methotrexate and tofacitinib impact these proteins, with distinct alterations corresponding to each drug's response, identifying potential candidates, as SAA4, for the response to these therapies.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:15 |
|---|---|
| Enthalten in: |
Frontiers in immunology - 15(2024) vom: 28., Seite 1333995 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Cuesta-López, Laura [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antirheumatic Agents |
|---|
| Anmerkungen: |
Date Completed 01.03.2024 Date Revised 08.04.2024 published: Electronic-eCollection Citation Status MEDLINE |
|---|
| doi: |
10.3389/fimmu.2024.1333995 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369100379 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369100379 | ||
| 003 | DE-627 | ||
| 005 | 20240409232521.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240301s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3389/fimmu.2024.1333995 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1370.xml |
| 035 | |a (DE-627)NLM369100379 | ||
| 035 | |a (NLM)38420123 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Cuesta-López, Laura |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Exploring candidate biomarkers for rheumatoid arthritis through cardiovascular and cardiometabolic serum proteome profiling |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 01.03.2024 | ||
| 500 | |a Date Revised 08.04.2024 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2024 Cuesta-López, Escudero-Contreras, Hanaee, Pérez-Sánchez, Ruiz-Ponce, Martínez-Moreno, Pérez-Pampin, González, Plasencia-Rodriguez, Martínez-Feito, Balsa, López-Medina, Ladehesa-Pineda, Rojas-Giménez, Ortega-Castro, Calvo-Gutiérrez, López-Pedrera, Collantes-Estévez, Arias-de la Rosa and Barbarroja. | ||
| 520 | |a Introduction: RA patients are at higher risk of cardiovascular disease, influenced by therapies. Studying their cardiovascular and cardiometabolic proteome can unveil biomarkers and insights into related biological pathways | ||
| 520 | |a Methods: This study included two cohorts of RA patients: newly diagnosed individuals (n=25) and those with established RA (disease duration >25 years, n=25). Both cohorts were age and sex-matched with a control group (n=25). Additionally, a longitudinal investigation was conducted on a cohort of 25 RA patients treated with methotrexate and another cohort of 25 RA patients treated with tofacitinib for 6 months. Clinical and analytical variables were recorded, and serum profiling of 184 proteins was performed using the Olink technology platform | ||
| 520 | |a Results: RA patients exhibited elevated levels of 75 proteins that might be associated with cardiovascular disease. In addition, 24 proteins were increased in RA patients with established disease. Twenty proteins were commonly altered in both cohorts of RA patients. Among these, elevated levels of CTSL1, SORT1, SAA4, TNFRSF10A, ST6GAL1 and CCL18 discriminated RA patients and HDs with high specificity and sensitivity. Methotrexate treatment significantly reduced the levels of 13 proteins, while tofacitinib therapy modulated the expression of 10 proteins. These reductions were associated with a decrease in DAS28. Baseline levels of SAA4 and high levels of BNP were associated to the non-response to methotrexate. Changes in IL6 levels were specifically linked to the response to methotrexate. Regarding tofacitinib, differences in baseline levels of LOX1 and CNDP1 were noted between non-responder and responder RA patients. In addition, response to tofacitinib correlated with changes in SAA4 and TIMD4 levels | ||
| 520 | |a Conclusion: In summary, this study pinpoints molecular changes linked to cardiovascular disease in RA and proposes candidate protein biomarkers for distinguishing RA patients from healthy individuals. It also highlights how methotrexate and tofacitinib impact these proteins, with distinct alterations corresponding to each drug's response, identifying potential candidates, as SAA4, for the response to these therapies | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Olink | |
| 650 | 4 | |a biomarkers | |
| 650 | 4 | |a methotrexate | |
| 650 | 4 | |a proximity extension assay (PEA) | |
| 650 | 4 | |a rheumatoid arthritis | |
| 650 | 4 | |a tofacitinib | |
| 650 | 7 | |a Methotrexate |2 NLM | |
| 650 | 7 | |a YL5FZ2Y5U1 |2 NLM | |
| 650 | 7 | |a Antirheumatic Agents |2 NLM | |
| 650 | 7 | |a Proteome |2 NLM | |
| 700 | 1 | |a Escudero-Contreras, Alejandro |e verfasserin |4 aut | |
| 700 | 1 | |a Hanaee, Yas |e verfasserin |4 aut | |
| 700 | 1 | |a Pérez-Sánchez, Carlos |e verfasserin |4 aut | |
| 700 | 1 | |a Ruiz-Ponce, Miriam |e verfasserin |4 aut | |
| 700 | 1 | |a Martínez-Moreno, Julio Manuel |e verfasserin |4 aut | |
| 700 | 1 | |a Pérez-Pampin, Eva |e verfasserin |4 aut | |
| 700 | 1 | |a González, Antonio |e verfasserin |4 aut | |
| 700 | 1 | |a Plasencia-Rodriguez, Chamaida |e verfasserin |4 aut | |
| 700 | 1 | |a Martínez-Feito, Ana |e verfasserin |4 aut | |
| 700 | 1 | |a Balsa, Alejandro |e verfasserin |4 aut | |
| 700 | 1 | |a López-Medina, Clementina |e verfasserin |4 aut | |
| 700 | 1 | |a Ladehesa-Pineda, Lourdes |e verfasserin |4 aut | |
| 700 | 1 | |a Rojas-Giménez, Marta |e verfasserin |4 aut | |
| 700 | 1 | |a Ortega-Castro, Rafaela |e verfasserin |4 aut | |
| 700 | 1 | |a Calvo-Gutiérrez, Jerusalem |e verfasserin |4 aut | |
| 700 | 1 | |a López-Pedrera, Chary |e verfasserin |4 aut | |
| 700 | 1 | |a Collantes-Estévez, Eduardo |e verfasserin |4 aut | |
| 700 | 1 | |a Arias-de la Rosa, Iván |e verfasserin |4 aut | |
| 700 | 1 | |a Barbarroja, Nuria |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Frontiers in immunology |d 2010 |g 15(2024) vom: 28., Seite 1333995 |w (DE-627)NLM215811453 |x 1664-3224 |7 nnns |
| 773 | 1 | 8 | |g volume:15 |g year:2024 |g day:28 |g pages:1333995 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3389/fimmu.2024.1333995 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 15 |j 2024 |b 28 |h 1333995 | ||